12:00 AM
 | 
May 12, 2014
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zontivity vorapaxar regulatory update

FDA approved an NDA for Zontivity vorapaxar from Merck to reduce thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). The label says the...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >